美国FDA已批准胸部放射学人工智能工具的现状与未来
该文综述了美国FDA已批准的放射学AI软件设备现状,其中190个获批设备中42个专门用于胸部放射学,主要用于肺结节检测与分析、气管插管和留置导管位置监测、急症发现检测及肺实质评估,并探讨了未来在间质性肺病评估、多源数据综合诊断及预后预测等方面的应用潜力。
要点
- 胸部放射学AI工具主要集中在肺结节检测与分析、导管位置监测和急症发现。
- FDA已批准190个放射学AI设备,其中42个针对胸部放射学。
- 未来方向包括间质性肺病评估、多模态数据综合诊断和预后预测。
核心结论
- FDA已批准190个放射学AI软件设备,其中42个专门用于胸部放射学。
- 当前胸部AI算法主要用于肺结节检测与分析、气管插管和留置导管位置监测、急症发现检测及肺实质评估。
- 未来潜在应用包括非特发性肺纤维化间质性肺病评估、影像与临床及实验室数据综合诊断、某些病变的生存或预后预测。
研究设计与样本
- 本文为综述,检索范围与纳入文献未在原文中报告。
- 原文未报告具体研究方法、样本量、中心数、设备或序列及参考标准。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准等诊断数值。
临床应用与阅片要点
- 日常阅片和报告可关注胸部AI在肺结节检测与分析、气管插管和留置导管位置监测、急症发现检测及肺实质评估方面的辅助价值。
- 需注意AI软件随数据输入持续演进而给传统FDA审批流程带来的挑战。
局限性
- 原文未报告研究局限性。
- 作为综述,原文未提供系统检索策略、纳入文献数量及证据分级信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Artificial intelligence (AI) is becoming more widespread within radiology. Capabilities that AI algorithms currently provide include detection, segmentation, classification, and quantification of pathological findings. Artificial intelligence software have created challenges for the traditional United States Food and Drug Administration (FDA) approval process for medical devices given their abilities to evolve over time with incremental data input. Currently, there are 190 FDA-approved radiology AI-based software devices, 42 of which pertain specifically to thoracic radiology. The majority of these algorithms are approved for the detection and/or analysis of pulmonary nodules, for monitoring placement of endotracheal tubes and indwelling catheters, for detection of emergent findings, and for assessment of pulmonary parenchyma; however, as technology evolves, there are many other potential applications that can be explored. For example, evaluation of non-idiopathic pulmonary fibrosis interstitial lung diseases, synthesis of imaging, clinical and/or laboratory data to yield comprehensive diagnoses, and survival or prognosis prediction of certain pathologies. With increasing physician and developer engagement, transparency and frequent communication between developers and regulatory agencies, such as the FDA, AI medical devices will be able to provide a critical supplement to patient management and ultimately enhance physicians' ability to improve patient care.
引用
- Milam, Koo. The current status and future of FDA-approved artificial intelligence tools in chest radiology in the United States. Clin Radiol. 2022. PMID: 36180271. doi:10.1016/j.crad.2022.08.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。